Cognitive FunctionNCT06294431
Radicle Clarity 24: A Study of Health and Wellness Products on Cognitive Function and Related Health Outcomes
A study testing Clarity Active Study Product 1.1 Usage and Clarity Active Study Product 2.1 Usage in people with Cognitive Function, run by Radicle Science at 1 site in United States.
Trial summary
A randomized, double-blind, placebo-controlled direct-to-consumer study of health and wellness products on cognitive function and related health outcomes Read more about this study
- Who is it for?
- Ages 21 to 105 yearsHealthy volunteers can take part
- Conditions the study is for
- Cognitive Function
- What is being tested?
- Clarity Active Study Product 1.1 Usage and Clarity Active Study Product 2.1 Usage
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 4,794 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Mar 2024to 15 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 105 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities. Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed
- Resides in the United States
- Endorses better concentration or cognitive function (fewer feelings of brain fog) as a primary desire
- Has the opportunity for at least 20% improvement in their primary health outcome
- Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Who cannot join
- Report being pregnant, trying to become pregnant, or breastfeeding
- Unable to provide a valid US shipping address and mobile phone number
- Reports current enrollment in another clinical trial
- Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
- Unable to read and understand English
- Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety lak
Show all 10Show fewer
- Reports a diagnosis or cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. NYHA (New York Heart Association) Class Ill or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
- Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOls (monoamine oxidase inhibitors), or thyroid products
- Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s)
- Lack of reliable daily access to the internet
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Radicle Clarity™ 24: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes
A randomized, double-blind, placebo-controlled direct-to-consumer study of health and wellness products on cognitive function and related health outcomes
Read the detailed description
This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States.
Eligible participants will (1) endorse a desire for better concentration, (2) have the opportunity for meaningful improvement (at least 20%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.
Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.
Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic, there are no in-person visits or assessments for this real-world evidence study.
- Conditions
- Cognitive Function
- Being tested
- Placebo Control Form 1, Clarity Active Study Product 1.1 Usage, Placebo Control Form 2, Clarity Active Study Product 2.1 Usage, Placebo Control Form 3
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo Control Form 1Dietary supplement
Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
Clarity Active Study Product 1.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
Placebo Control Form 2Dietary supplement
Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
Clarity Active Study Product 2.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
Placebo Control Form 3Dietary supplement
Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
Clarity Active Study Product 3.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
Clarity Active Study Product 3.2 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 3.2 as directed for a period of 6 weeks.
Placebo Control Form 4Dietary supplement
Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
Clarity Active Study Product 4.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
Placebo Control Form 5Dietary supplement
Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
Clarity Active Study Product 5.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
Clarity Active Study Product 5.2 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
Placebo Control Form 6Dietary supplement
Participants will use their Placebo Control Form 6 as directed for a period of 6 weeks.
Clarity Active Study Product 6.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 6.1 as directed for a period of 6 weeks.
Placebo Control 6.1.0Dietary supplement
Participants will use their Placebo Control 6.1.0 as directed for a period of 6 weeks.
Clarity Active Study Product 6.1.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 6.1.1 as directed for a period of 6 weeks.
Clarity Active Study Product 6.1.2 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 6.1.2 as directed for a period of 6 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Placebo Control 1 | Placebo comparator | Clarity Product Form 1 - control Receives: Dietary Supplement: Placebo Control Form 1 |
| Active Product 1.1 | Experimental | Clarity Product Form 1 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 1.1 Usage |
| Placebo Control 2 | Placebo comparator | Clarity Product Form 2 - control Receives: Dietary Supplement: Placebo Control Form 2 |
| Active Product 2.1 | Experimental | Clarity Product Form 2 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 2.1 Usage |
| Placebo Control 3 | Placebo comparator | Clarity Product Form 3 - control Receives: Dietary Supplement: Placebo Control Form 3 |
| Active Product 3.1 | Experimental | Clarity Product Form 3 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 3.1 Usage |
| Active Product 3.2 | Experimental | Clarity Product Form 3 - active product 2 Receives: Dietary Supplement: Clarity Active Study Product 3.2 Usage |
| Placebo Control 4 | Placebo comparator | Clarity Product Form 4 - control Receives: Dietary Supplement: Placebo Control Form 4 |
| Active Product 4.1 | Experimental | Clarity Product Form 4 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 4.1 Usage |
| Placebo Control 5 | Placebo comparator | Clarity Product Form 5 - control Receives: Dietary Supplement: Placebo Control Form 5 |
| Active Product 5.1 | Experimental | Clarity Product Form 5 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 5.1 Usage |
| Active Product 5.2 | Experimental | Clarity Product Form 5 - active product 2 Receives: Dietary Supplement: Clarity Active Study Product 5.2 Usage |
| Placebo Control 6 | Placebo comparator | Clarity Product Form 6 - control Receives: Dietary Supplement: Placebo Control Form 6 |
| Active Product 6.1 | Experimental | Clarity Product Form 6 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 6.1 Usage |
| Placebo Control 6.1.0 | Placebo comparator | Clarity Product 6.1.0 - control Receives: Dietary Supplement: Placebo Control 6.1.0 |
| Active Product 6.1.1 | Experimental | Clarity Product 6.1.1 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 6.1.1 Usage |
| Active product 6.1.2 | Experimental | Clarity Product 6.1.2 Receives: Dietary Supplement: Clarity Active Study Product 6.1.2 Usage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in cognitive function
Mean difference in cognition function score as assessed by Patient Reported Outcome Measurement System (PROMIS) Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function)
Measured: 6 weeks
Secondary outcomes (3)
Change in fatigue
Mean difference in fatigue score as assessed by PROMIS Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue)
Measured: 6 weeks
Change in sleep-related impairment
Mean difference in sleep-related impairment score as assessed by PROMIS Sleep-Related Impairment 4A (scale 4-20; with higher scores corresponding to greater sleep-related impairment)
Measured: 6 weeks
Minimal clinical importance difference (MCID) in cognitive function
Likelihood of achieving a MCID in cognitive function, as measured by PROMIS Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function)
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2024
- Study start4 Mar 2024
- Primary completion15 Aug 2025
- Study completion15 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cognitive FunctionStudies of the same condition, open and under way.
- More trials run by Radicle ScienceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be stratified based on their gender assigned at birth and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 4,794 participants (actual)
Sponsor and investigators
- Lead sponsor
- Radicle Science
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Emily K. Pauli, PharmD, Principal investigator, Radicle Science Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06294431
- Sponsor's protocol ID
- RADX-P-2406
- Status last verified
- Mar 2025
- First submitted
- 21 Feb 2024
- Last updated
- 2 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will not be shared with researchers outside of Radicle Collaborators on this study.
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Radicle Clarity™ 24: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes
- ClinicalTrials.gov ID
- NCT06294431
- Acronym / sponsor ID
- RADX-P-2406
- Conditions
- Cognitive Function
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 4,794 participants (actual)
- Lead sponsor
- Radicle ScienceIndustry (pharma, biotech, devices)
- Study start
- 4 Mar 2024 (actual)
- Primary completion
- 15 Aug 2025 (actual)
- Study completion
- 15 Aug 2025 (actual)
- First posted
- 5 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A randomized, double-blind, placebo-controlled direct-to-consumer study of health and wellness products on cognitive function and related health outcomes
Detailed description
This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States.
Eligible participants will (1) endorse a desire for better concentration, (2) have the opportunity for meaningful improvement (at least 20%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.
Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.
Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic, there are no in-person visits or assessments for this real-world evidence study.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 17
- Model description
- Participants will be stratified based on their gender assigned at birth and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.
| Arm | Type | Receives |
|---|---|---|
| Placebo Control 1 | Placebo comparator | Dietary Supplement: Placebo Control Form 1Clarity Product Form 1 - control |
| Active Product 1.1 | Experimental | Dietary Supplement: Clarity Active Study Product 1.1 UsageClarity Product Form 1 - active product 1 |
| Placebo Control 2 | Placebo comparator | Dietary Supplement: Placebo Control Form 2Clarity Product Form 2 - control |
| Active Product 2.1 | Experimental | Dietary Supplement: Clarity Active Study Product 2.1 UsageClarity Product Form 2 - active product 1 |
| Placebo Control 3 | Placebo comparator | Dietary Supplement: Placebo Control Form 3Clarity Product Form 3 - control |
| Active Product 3.1 | Experimental | Dietary Supplement: Clarity Active Study Product 3.1 UsageClarity Product Form 3 - active product 1 |
| Active Product 3.2 | Experimental | Dietary Supplement: Clarity Active Study Product 3.2 UsageClarity Product Form 3 - active product 2 |
| Placebo Control 4 | Placebo comparator | Dietary Supplement: Placebo Control Form 4Clarity Product Form 4 - control |
| Active Product 4.1 | Experimental | Dietary Supplement: Clarity Active Study Product 4.1 UsageClarity Product Form 4 - active product 1 |
| Placebo Control 5 | Placebo comparator | Dietary Supplement: Placebo Control Form 5Clarity Product Form 5 - control |
| Active Product 5.1 | Experimental | Dietary Supplement: Clarity Active Study Product 5.1 UsageClarity Product Form 5 - active product 1 |
| Active Product 5.2 | Experimental | Dietary Supplement: Clarity Active Study Product 5.2 UsageClarity Product Form 5 - active product 2 |
| Placebo Control 6 | Placebo comparator | Dietary Supplement: Placebo Control Form 6Clarity Product Form 6 - control |
| Active Product 6.1 | Experimental | Dietary Supplement: Clarity Active Study Product 6.1 UsageClarity Product Form 6 - active product 1 |
| Placebo Control 6.1.0 | Placebo comparator | Dietary Supplement: Placebo Control 6.1.0Clarity Product 6.1.0 - control |
| Active Product 6.1.1 | Experimental | Dietary Supplement: Clarity Active Study Product 6.1.1 UsageClarity Product 6.1.1 - active product 1 |
| Active product 6.1.2 | Experimental | Dietary Supplement: Clarity Active Study Product 6.1.2 UsageClarity Product 6.1.2 |
Who may qualify
- Ages
- 21 to 105 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities. Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed
- Resides in the United States
- Endorses better concentration or cognitive function (fewer feelings of brain fog) as a primary desire
- Has the opportunity for at least 20% improvement in their primary health outcome
- Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Key exclusion criteria (10 listed)
- Report being pregnant, trying to become pregnant, or breastfeeding
- Unable to provide a valid US shipping address and mobile phone number
- Reports current enrollment in another clinical trial
- Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
- Unable to read and understand English
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo Control Form 1Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 1 |
| Clarity Active Study Product 1.1 UsageParticipants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 1.1 |
| Placebo Control Form 2Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 2 |
| Clarity Active Study Product 2.1 UsageParticipants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 2.1 |
| Placebo Control Form 3Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 3 |
| Clarity Active Study Product 3.1 UsageParticipants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 3.1 |
| Clarity Active Study Product 3.2 UsageParticipants will use their Radicle Clarity Active Study Product 3.2 as directed for a period of 6 weeks. | Dietary supplement | Active Product 3.2 |
| Placebo Control Form 4Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 4 |
| Clarity Active Study Product 4.1 UsageParticipants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 4.1 |
| Placebo Control Form 5Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 5 |
| Clarity Active Study Product 5.1 UsageParticipants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 5.1 |
| Clarity Active Study Product 5.2 UsageParticipants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks. | Dietary supplement | Active Product 5.2 |
| Placebo Control Form 6Participants will use their Placebo Control Form 6 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 6 |
| Clarity Active Study Product 6.1 UsageParticipants will use their Radicle Clarity Active Study Product 6.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 6.1 |
| Placebo Control 6.1.0Participants will use their Placebo Control 6.1.0 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 6.1.0 |
| Clarity Active Study Product 6.1.1 UsageParticipants will use their Radicle Clarity Active Study Product 6.1.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 6.1.1 |
| Clarity Active Study Product 6.1.2 UsageParticipants will use their Radicle Clarity Active Study Product 6.1.2 as directed for a period of 6 weeks. | Dietary supplement | Active product 6.1.2 |
Primary outcome
Change in cognitive function
Time frame: 6 weeks
Mean difference in cognition function score as assessed by Patient Reported Outcome Measurement System (PROMIS) Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function)
3 secondary outcomes
Change in fatigue
Time frame: 6 weeks
Change in sleep-related impairment
Time frame: 6 weeks
Minimal clinical importance difference (MCID) in cognitive function
Time frame: 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2025.
- Radicle Science, IncLink provided by the sponsor.
- Individual participant dataSharing planned: No. Data will not be shared with researchers outside of Radicle Collaborators on this study.
Related trials for Cognitive Function
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Emily K. Pauli, PharmD principal investigator
Radicle Science Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clarity Active Study Product 1.1 Usage and Clarity Active Study Product 2.1 Usage in people with Cognitive Function, run by Radicle Science at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in cognitive function (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2025.